Sélectionner la langue
CCR8
CCR8 Informations sur la molécule
| Nom anglais | C-C chemokine receptor type 8 | Nombre de médicaments commercialisés | 0 |
| Nombre de médicaments cliniques | 21 | Alias de la cible | Chemokine (C-C) Receptor 8，CC Chemokine Receptor 8，CDw198 Antigen，C-C CKR-8，CC-CKR-8，CCR-8，CMKBRL2，C-C Motif Chemokine Receptor 8，CC chemokine receptor CHEMR1，C-C chemokine receptor type 8，Chemokine (C-C Motif) Receptor 8，C-C Chemokine Receptor Type 8，CC Chemokine Receptor CHEMR1，Chemokine Receptor-Like 1，Chemokine (C-C) Receptor-Like 2，CC-Chemokine Receptor Chemr1，CD_antigen=CDw198，Chemokine receptor-like 1，CKRL1，CKR-L1，CMKBR8，GPRCY6，GPR-CY6，TER1，CDw198，CY6 |
| Phase de R&D la plus avancée | Phase 3 Clinical | ||
| Nom anglais | C-C chemokine receptor type 8 |
| Alias de la cible | Chemokine (C-C) Receptor 8，CC Chemokine Receptor 8，CDw198 Antigen，C-C CKR-8，CC-CKR-8，CCR-8，CMKBRL2，C-C Motif Chemokine Receptor 8，CC chemokine receptor CHEMR1，C-C chemokine receptor type 8，Chemokine (C-C Motif) Receptor 8，C-C Chemokine Receptor Type 8，CC Chemokine Receptor CHEMR1，Chemokine Receptor-Like 1，Chemokine (C-C) Receptor-Like 2，CC-Chemokine Receptor Chemr1，CD_antigen=CDw198，Chemokine receptor-like 1，CKRL1，CKR-L1，CMKBR8，GPRCY6，GPR-CY6，TER1，CDw198，CY6 |
| Nombre de médicaments commercialisés | 0 |
| Nombre de médicaments cliniques | 21 |
| Phase de R&D la plus avancée | Phase 3 Clinical |
CCR8 Liste de produits
- Attribut
Protein (8)Cell (1)Antibody (1)
- Bibliothèque de produits
En ligne (10)
- Espèces
Human (7)Mouse (2)Rhesus macaque (1)
- Étiquette
His Tag & Flag Tag (1)- (7)His Tag & Flag Tag & Strep Tag (2)
- Marqueur
Unconjugated (7)- (1)Biotin-labeled (2)
Ajouter au panier
Quantité totale10
- 1
CCR8Contexte de la molécule
This entry represents CC chemokine receptor 8 (CCR8), which it is expressed predominantly in lymphoid tissues and has also been found in glomerular podocytes and human umbilical vein endothelial cells (HUVECs). CCR8 is associated with Th2 lymphocytes, which are critical for allergy, and has a role in lymphocyte activation, migration, proliferation and differentiation and in allergic diseases. CCR8 binds to CCL1 (also known as I-309) and to CCL16 (also known as liver expressed chemokine). It also exhibits a high affinity for three chemokines of viral origin: vMIP-I, vMIP-II and vMCC-I.
CCR8Alias de la molécule
CC chemokine receptor 8,CDw198,ChemR1,CKRL1,CKR-L1,CKRL1,CY6,GPRCL1,GPRCY6,GPR-CY6,TER-1
Plateforme de commerce de projets d'anticorps
| Nom du projet | Phase du projet | Type de molécule | Source de molécule | Domain thérapeutique | Indication |
|---|---|---|---|---|---|
| CCR8 mAb - 01 | PCC | Monoclonal | Humanized Mouse | Solid Tumor | Solid tumor |
| CCR8 mAb - 02 | Lead | Monoclonal | Humanized Mouse | Solid Tumor | Solid tumor |
| CCR8 mAb - 03 | PCC | Monoclonal | Humanized Mouse | Solid Tumor | Solid tumor |
Coopération sous licence
| Nom du projet | Type de médicament | Domain thérapeutique | Indication | Phase | Zone de droits |
|---|---|---|---|---|---|
| CCR8 Humanized Antibody | Bispecific antibody | Oncology/Cancer | Solid Tumor | Preclinical | Global |
Informations sur les médicaments cliniques
| Nom anglais | Code de recherche | Phase de R&D | Entreprise | Indication | Essai clinique |
|---|---|---|---|---|---|
| Cafelkibart | LM-108 | Phase 3 Clinical | LaNova Medicines Ltd | Carcinoma, Non-Small-Cell Lung; Gastroesophageal Junction Neoplasms; Pancreatic Neoplasms; Solid tumours; Stomach Neoplasms; Triple Negative Breast Neoplasms | Details |
| Imzokitug | BMS-986340; ONO-7427 | Phase 2 Clinical | Eeig Bristol-Myers Squibb Manufacturing Company Bristol-Myers Squibb Srl | Carcinoma, Non-Small-Cell Lung; Carcinoma, Renal Cell; Carcinoma, Transitional Cell; Colorectal Neoplasms; Esophageal Neoplasms; Melanoma; Neoplasms; Ovarian Neoplasms; Pancreatic Neoplasms; Solid tumours; Squamous Cell Carcinoma of Head and Neck; Triple Negative Breast Neoplasms; Uterine Cervical Neoplasms | Details |
| TAK- 188 | TAK- 188 | Phase 2 Clinical | Takeda Pharmaceutical Co Ltd | Solid tumours | Details |
| QLP2117 | QLP2117; QLP-2117 | Phase 2 Clinical | Qilu Pharmaceutical Co Ltd | Neoplasms; Solid tumours | Details |
| DT-7012 | DT-7012 | Phase 2 Clinical | Domain Therapeutics SA | Lymphoma, T-Cell, Cutaneous; Mycosis Fungoides; Neoplasms; Sezary Syndrome; Solid tumours | Details |
| S-531011 | S-531011 | Phase 2 Clinical | Shionogi Inc | Solid tumours | Details |
| IPG-7236 | IPG-7236 | Phase 2 Clinical | Nanjing Immunophage Biotech Co Ltd | Breast Neoplasms; Dermatitis, Atopic; Solid tumours | Details |
| anti-CCR8 antibody (Bristol-Myers Squibb) | Phase 1 Clinical | Bristol-Myers Squibb Company | Solid tumours | Details | |
| PSB-114 | PSB-114 | Phase 1 Clinical | Qilu Puget Sound Biotherapeutics Corp | Neoplasms | Details |
| BAY-3375968 | BAY-3375968 | Phase 1 Clinical | Bayer AG | Neoplasms; Solid tumours | Details |
| ICP-B05 | ICPB05; CM-369 | Phase 1 Clinical | InnoCare Pharma Ltd, Keymed Biosciences Co Ltd | Hematologic Neoplasms; Solid tumours | Details |
| HBM-1022 | HBM-1022 | Phase 1 Clinical | Harbour Biomed | Neoplasms | Details |
| Denikitug | JTX-1811; GS-1811 | Phase 1 Clinical | Jounce Therapeutics Inc | Solid tumours | Details |
| Tagmokitug | CHS-114; SRF-114 | Phase 1 Clinical | Surface Oncology Inc | Neoplasms; Solid tumours; Squamous Cell Carcinoma of Head and Neck | Details |
| TQB-6457 | TQB-6457; TQB6457 | Phase 1 Clinical | Shanghai Chia Tai Tianqing Pharmaceutical Technology Development Co Ltd | Neoplasms | Details |
| KYS-2301 | KYS2301; KYS-2301 | Phase 1 Clinical | Jiangsu Kanion Pharmaceutical Co Ltd | Dermatitis, Atopic | Details |
| AMG-355 | AMG 355; AMG-355 | Phase 1 Clinical | Amgen Inc | Solid tumours | Details |
| HC-006 | HC-006; HC006 | Phase 1 Clinical | Shanghai Hongcheng Pharmaceutical Co Ltd | Neoplasms; Solid tumours | Details |
| BGB-A3055 | BGB-A3055 | Phase 1 Clinical | BeOne Medicines Ltd | Solid tumours | Details |
| ABBV-514 | ABBV-514 | Phase 1 Clinical | Abbvie Inc | Carcinoma, Non-Small-Cell Lung; Colorectal Neoplasms; Cystadenocarcinoma, Serous; Ovarian Neoplasms; Pancreatic Neoplasms; Squamous Cell Carcinoma of Head and Neck; Triple Negative Breast Neoplasms | Details |
| IPGA-05 | IPGA-05; IPG0521; IPG-0521 | Phase 1 Clinical | Nanjing Immunophage Biotech Co Ltd | Autoimmune Diseases; Immunoglobulin G4-Related Disease; Solid tumours | Details |
- Informations sur la molécule
- Liste de produits
- Informations sur les médicaments cliniques
Partager vers :